Adank C, Koerner F
Ophthalmologica. 1985;190(2):102-11. doi: 10.1159/000309502.
The effect of calcium dobesilate (Doxium) therapy on the evolution of diabetic retinopathy has been assessed in a retrospective study. 54 patients with diabetic retinopathy received calcium dobesilate (average 650 mg/day) for 6-30 months (average 18 months) and were compared to a correspondingly selected control group. The patients were divided into three subgroups (mild, moderate, and severe diabetic retinopathy). Microaneurysms, blot hemorrhages, striate hemorrhages, and hard exudates were assessed semiquantitatively from panorama fundus photographs, using a scoring system. The effect of calcium dobesilate was statistically significant for cases with moderate background diabetic retinopathy on summing up the scores of the various retinal lesions. There was no favorable effect on diabetic maculopathy or visual acuity. In the proliferative stages of diabetic retinopathy, photocoagulation is offering, in the majority of cases, the only chance to slow down the progression of this disease; however, drug therapy might be beneficial in nonproliferative diabetic retinopathy.
一项回顾性研究评估了羟苯磺酸钙（多贝斯）治疗对糖尿病视网膜病变进展的影响。54例糖尿病视网膜病变患者接受了羟苯磺酸钙治疗（平均每日650毫克），疗程为6至30个月（平均18个月），并与相应选择的对照组进行比较。患者被分为三个亚组（轻度、中度和重度糖尿病视网膜病变）。使用评分系统，从全景眼底照片中对微动脉瘤、点状出血、线状出血和硬性渗出进行半定量评估。对于中度背景性糖尿病视网膜病变患者，在总结各种视网膜病变的评分时，羟苯磺酸钙的效果具有统计学意义。对糖尿病黄斑病变或视力没有有利影响。在糖尿病视网膜病变的增殖期，在大多数情况下，光凝是减缓该疾病进展的唯一机会；然而，药物治疗可能对非增殖性糖尿病视网膜病变有益。
